EB-NK-301

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameEB-NK-301
Drug Alias NameAllogeneic TROP2-CAR NK Cells therapy (Beijing Biotech)EB-NK-301
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionTumor-associated calcium signal transducer 2 modulatorsNatural killer cell replacements
TargetsTumor-associated calcium signal transducer 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Biotech
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A